Lipigon Pharmaceuticals AB (publ) (FRA:9RP)

Market Cap	83.75K -93.5%
Revenue (ttm)	n/a
Net Income	-3.00M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0001 - 0.0168
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 8, 2026

About FRA:9RP

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid-related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease; and CAP project, which is in preclinical trial to treat and prevent lung damages associated with community-acquired pneumonia. The company has a license agreement with Leaderna for the development of Lipis...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9RP

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Aug 27, 2026

Data Sources Report a data error